2017
DOI: 10.5114/pr.2017.72539
|View full text |Cite
|
Sign up to set email alerts
|

CCSVI in multiple sclerosis: is it the end?

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2018
2018
2018
2018

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
(1 citation statement)
references
References 6 publications
(7 reference statements)
0
1
0
Order By: Relevance
“…The Italian study has, however, demonstrated that patients who received the treatment had no new MRI-detectable lesions (this composite is routinely used for the assessment of the pharmacological agent used in the treatment of MS). This effect was not statistically significant but could have reached the level of p < 0.05 if more patents had been recruited [22,23]. This effect, however, was seen only in a subgroup of patients.…”
Section: Marian Simkamentioning
confidence: 84%
“…The Italian study has, however, demonstrated that patients who received the treatment had no new MRI-detectable lesions (this composite is routinely used for the assessment of the pharmacological agent used in the treatment of MS). This effect was not statistically significant but could have reached the level of p < 0.05 if more patents had been recruited [22,23]. This effect, however, was seen only in a subgroup of patients.…”
Section: Marian Simkamentioning
confidence: 84%